Home › Funds › Crystal Rock Capital Management › BSX

Crystal Rock Capital Management position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Crystal Rock Capital Management reported holding 29,670 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$1.3M, representing 0.68% of its reported portfolio and ranking #32 among its reported holdings. Crystal Rock Capital Management has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)29.67K sh
Reported value held$1.30M
Portfolio Weight0.68%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Crystal Rock Capital Management's BSX position evolved

Crystal Rock Capital Management first disclosed a stake in BSX in Q3 2023 at 99,375 shares (US$5.2M). The position peaked in Q3 2024 at 91,525 shares, worth US$7.7M. Across 13 filings, Crystal Rock Capital Management increased the stake 0 time(s), trimmed it 9 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 29,670 shares valued at US$1.3M — a reduction of -17,575 shares quarter over quarter.. Notable position changes include a 37% trim in Q3 2026 (shares rose 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 99.38K $5.25M New
Q4 2023 94.88K $5.48M Reduce
Q1 2024 94.88K $6.50M Hold
Q2 2024 94.88K $7.31M Hold
Q3 2024 91.53K $7.67M Reduce
Q4 2024 85.10K $7.60M Reduce
Q1 2025 69.32K $6.99M Reduce
Q2 2025 64.77K $6.96M Reduce
Q3 2025 59.02K $5.76M Reduce
Q4 2025 59.02K $5.63M Hold
Q1 2026 50.65K $3.18M Reduce
Q2 2026 47.24K $2.02M Reduce
Q3 2026 29.67K $1.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Crystal Rock Capital Management held BSX?

Crystal Rock Capital Management has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Crystal Rock Capital Management's current position in BSX?

As of Q3 2026, Crystal Rock Capital Management holds 29.67K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $1.30M, representing 0.68% of its reported portfolio and ranking #32.

Has Crystal Rock Capital Management been buying or selling BSX?

In the latest 13F filing (Q3 2026), Crystal Rock Capital Management reduced its position in BSX. The position peaked in Q3 2024 at 91.53K shares.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 18 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.